
    
      The objectives of this study are:

      To evaluate the long-term safety of Artefill injection volumes that are three to four times
      greater (i.e. up to 30 ml) than the volume indicated in the FDA approved product label (i.e.
      8.9 ml)subjects with HIV.

      To evaluate any adverse events associated with the use of Artefill. To evaluate the Quality
      of Life and body image benefit from Artefill treatment in patients with lipoatrophy.
    
  